Study of NS5B gene mutations in hepatitis C virus genotype 1a in Guilan Province

Subject Areas : Virology

Leila Asadpour ¹ (Assistant Professor, Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran.)
Hamdollah Rahimi Dogaheh ² (M.Sc., Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.)
Mahnaz Houshmsnd Rad ³ (M.Sc., Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.)

Received: 2018-06-06 Accepted : 2018-07-03 Published : 2019-02-20

Keywords: Drug resistance, Hepatitis C, NS5B mutation,

Abstract :

Background & Objectives: Hepatitis C virus is the main cause of chronic hepatitis, resulting in a thousand deaths every year. NS5B protein is an RNA-dependent RNA polymerase that is encoded by the NS5B gene and involved in virus replication. One of the most effective drugs in the treatment of infections caused by this virus are NS5B protein inhibitors. The emergence of the strains resistant to these drugs is a major obstacle to the success of treatment. The aim of this study was to investigate possible mutations in the NS5B region of hepatitis C virus genotype 1a in Guilan province.   Materials & Methods: HCV genomic RNA was extracted from the plasma samples of 225 anti-HCV positive patients and its molecular identification and genotyping was carried out by RT-PCR and product Sequencing. Then, the NS5B gene was amplified in 10 strains with genotype 1a and subsequently sequenced to determine mutations in this region.   Results: Genotypes 3a (53.3%) and 1a (36.9%) were the most abundant genotypes identified in Guilan. According to sequencing results, out of 10 investigated genotype 1a strains, 5 strains showed 7 types of missense mutations in codons Q309, A327, S254, K304, N307, R250, and A334.   Conclusions: Genotype 1a is one of the common genotypes of hepatitis C virus in Guilan. Identifying mutations or polymorphisms associated with resistance in hepatitis C virus can be useful in optimizing the treatment and determining the efficacy of drugs in treating hepatitis C virus.

References:

1. Von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG,
   Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV
   vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
   Vaccine. 2018; 36(2): 313-321.
   2. Chantratita W, Song KS, Gun Ho C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G,
   Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD. 6 HCV genotyping 9G test
   and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus
   genotyping. J Virol Methods. 2017; 239: 1-8.
   3. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S, Houchen CW.
   Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor
   xenografts. J Virol. 2011; 85(23): 12292-12303.
   4. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global
   distribution and prevalence of hepatitis C virus genotypes. Hepatol. 2015; 61(1): 77-87.
   5. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med. 2001; 345(1): 41-52.
   6. Bennett JE, Dolin R, Blaser MJ. Principles and practice of infectious diseases. Elsevier Health
   Sci; 2014; 1: 1336-1356.
   7. Ranjith-Kumar CT, Kao CC. Biochemical activities of the HCV NS5B RNA-dependent RNA
   polymerase. Hepatitis C viruses: Genomes and molecular biology. Norfolk (UK): Horizon
   Bioscience. 2006: 293-310.
   8. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection.
   
   Therap Adv Gastroenterol. 2010; 3(3): 191-202.
   9. Motawi TM, Rizk SM, Shaker OG, Mokhtar OZ. MicroRNAs as predictor markers for response
   to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients. PloS one. 2015; 10
   (3): 1-12.
   10. Castilho MC, Martins AN, Horbach IS, Perez RD, Figueiredo FA, Pinto PD, Nabuco LC, Lima
   DB, Tanuri A, Porto LC, Júnior F. Association of hepatitis C virus NS5B variants with resistance
   to new antiviral drugs among untreated patients. Mem Inst Oswaldo Cruz. 2011; 106(8):
   968-975.
   11. Huang T, Wang J, Cai YD, Yu H, Chou KC. Hepatitis C virus network based classification of
   hepatocellular cirrhosis and carcinoma. PLoS One. 2012; 7(4): e34460.
   12. Hosseini Moghaddam SM, Keyvani H, Kasiri H, Kazemeyni SM, Basiri A, Aghel N, Alavian
   SM. Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran: a
   multicenter study. J Med Virol. 2006; 78(5): 569-573.
   13. Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its
   significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect
   Dis. 2008; 61(4): 408-414.
   14. Haghshenas MR, Babamahmoodi F, Rafiei AR, Vahedi V. The correlation between HCV
   genotypes and liver damage in HCV patients. J Mazandaran Uni Med Sci. 2011; 21(85): 76-83.
   15. Samimi Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of
   hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol.
   2004; 74(2): 246-252.
   16. Makhloogh A, Aezinia N, Haghshenas MR, Tirgar-fakheri H, Maleki I, Taghvaei T.
   Comparison of Hepatitis C Virus Genotypes in Hemodialysis and Nonuremic Patients.
   Armaghane Danesh. 2010; 15(3): 283-292. [In Persian]
   17. Hejazi MS, Ghotaslou R, Farshdoosty Hagh M, Mohammadzadeh Sadigh Y. Genotyping of
   hepatitis C virus in northwest of Iran. Biotechnol. 2007; 6(3): 302-308.
   18. Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of
   amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral
   isolates and comparison with worldwide isolates. Virol J. 2012; 9(1): 214.
   19. Kim DW, Lee SA, Kim H, Won YS, Kim BJ. Naturally occurring mutations in the
   nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients
   chronically infected with HCV genotype 1b. PLOS One. 2014; 9(1): e87773.
   20. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, Bruno R, Baldanti F.
   Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B
   polymerase in DAA treatment-naive patients. Virol J. 2013; 10(1): 355.